Integrative Genome-Wide Expression and Promoter DNA Methylation Profiling Identifies a Potential Novel Panel of Ovarian Cancer Epigenetic Biomarkers

Cancer Lett. 2012 May 1;318(1):76-85. doi: 10.1016/j.canlet.2011.12.003. Epub 2011 Dec 9.


To identify epigenetic-based biomarkers for diagnosis of ovarian cancer we performed MeDIP-Chip in A2780 and CaOV3 ovarian cancer cell lines. Validation by Sequenom massARRAY methylation analysis confirmed a panel of six gene promoters (ARMCX1, ICAM4, LOC134466, PEG3, PYCARD & SGNE1) where hypermethylation discriminated 27 serous ovarian cancer clinical samples versus 12 normal ovarian surface epithelial cells (OSE) (ROC of 0.98). Notably, CpG sites across the transcription start site of a potential long-intergenic non-coding RNA (lincRNA) gene (LOC134466), was shown to be hypermethylated in 81% of serous EOC and could differentiate tumours from OSE (p<0.05). We propose that this potential biomarker panel holds great promise as a diagnostic test for high-grade (Type II) serous ovarian cancer.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers / analysis*
  • CpG Islands / genetics
  • Cystadenocarcinoma, Serous / genetics
  • DNA Methylation*
  • Epigenomics*
  • Female
  • Gene Expression Profiling*
  • Gene Expression Regulation, Neoplastic
  • Genes, Tumor Suppressor
  • Genome, Human*
  • Humans
  • Oligonucleotide Array Sequence Analysis
  • Ovarian Neoplasms / genetics*
  • Ovary / metabolism
  • Ovary / pathology
  • Promoter Regions, Genetic / genetics*
  • Tumor Cells, Cultured


  • Biomarkers